In a space where a growing number of individuals are qualifying for Medicare, Astiva Health is differentiating itself as a fast-growing Medicare Advantage Prescription Drug (“MAPD”) health plan focused on redefining the standards of personalized and comprehensive healthcare. As an indication of its success in, Astiva company recently reached a key milestone, surpassing the 10,000-member mark (https://ibn.fm/bQ6jM).
“Enrollment in Medicare Advantage is projected to increase from 31.6 million in 2023 to 33.8 million in 2024,” stated a release from the Centers for Medicare and Medicaid Services (“CMS”) (https://ibn.fm/b5H40). “The projected Medicare Advantage enrollment in 2024 will represent approximately 50% of all people enrolled in Medicare, compared to approximately 48% for 2023.”
The press release went on to quote CMS deputy administrator and director of the Center for Medicare Meena Seshamani, MD, PhD, who said: “Today’s release shows that, as expected, people with Medicare will continue to have robust options and stable benefit offerings in the MA market.”
Astiva is one of the companies committed to providing those robust and stable offerings to a growing number of people looking for the best Medicare options. Reaching the 10,000-member milestone — a substantial increase from Astiva’s 4,700 members in September 2023 — came in part from the company’s recent strategic expansion into the California counties of Los Angeles, Riverside, and San Bernardino. According to the company, the expansion, which went into effect on Jan. 1, 2024, marks a pivotal moment in Astiva Health’s mission to reshape healthcare delivery and increased access to quality healthcare for a diverse range of individuals in Southern California.
“Astiva Health’s rapid growth to over 10,000 members reflects our commitment to providing personalized and culturally responsive healthcare,” said Astiva Health cofounder and CEO Dr. Tri T. Nguyen. “Our expansion into these three counties has not only allowed us to serve a wider community but also to deepen our impact in meeting the unique healthcare needs of our members.”
Astiva is working to achieve its goal of redefining the standards of personalized and comprehensive healthcare by focusing on improving member services, comprehensive medical care, prescription drugs, and great supplemental benefits. In addition, the company’s commitment to offer multilingual solutions and educational resources means that its members experience care that is both effective and culturally sensitive.
“This membership increase is a testament to Astiva Health’s robust and member-centric approach, which prioritizes building lasting relationships and addressing the unique needs of its members,” the company states. “It also signifies the trust and confidence that the community places in Astiva Health as their healthcare provider.”
Astiva Health is a fast-growing MAPD health plan committed to redefining the standards of personalized and comprehensive healthcare. With a mission to elevate the well-being of individuals, Astiva Health specializes in innovative health plans tailored to meet the unique requirements of its members.
The organization prioritizes a culturally responsive approach to healthcare and is dedicated to serving the underserved population, not only fulfilling a critical societal need but also positioning the company to tap into a market segment with significant growth potential. By addressing the diverse healthcare needs of its members, Astiva Health aims to create lasting relationships and contribute to the overall well-being of the communities it serves.
For more information, visit the company’s website at www.AstivaHealth.com.
NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva
About BioMedWire
BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visit https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered by IBN
Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective…
A team of researchers has leveraged a technique called temporal learning to train an AI…
Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year…
“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected…
Adageis offers an AI-powered financial technology platform tailored to healthcare providers seeking a financially positive…
A new study focusing on twins has found that individuals with a larger presence of…